Elmar Schnee Net Worth

The estimated Net Worth of Elmar Schnee is at least 2.08 百万$ dollars as of 5 August 2021. Mr. Schnee owns over 1,632 units of Jazz Pharmaceuticals plc stock worth over 869,425$ and over the last 10 years he sold JAZZ stock worth over 663,900$. In addition, he makes 542,573$ as Independent Director at Jazz Pharmaceuticals plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Schnee JAZZ stock SEC Form 4 insiders trading

Elmar has made over 4 trades of the Jazz Pharmaceuticals plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,632 units of JAZZ stock worth 251,328$ on 5 August 2021.

The largest trade he's ever made was selling 1,632 units of Jazz Pharmaceuticals plc stock on 5 August 2021 worth over 251,328$. On average, Elmar trades about 488 units every 162 days since 2014. As of 5 August 2021 he still owns at least 8,270 units of Jazz Pharmaceuticals plc stock.

You can see the complete history of Mr. Schnee stock trades at the bottom of the page.

Elmar Schnee biography

Elmar J. Schnee serves as Independent Director of the Company. Mr. Schnee has served as a member of our board of directors since August 2014 and previously served as a director of Gentium (now a subsidiary of Jazz Pharmaceuticals plc) from May 2012 until April 2014. Mr. Schnee has served as Chief Operating Officer of MindMaze SA, a neuro-technology company, since June 2016. From November 2013 to August 2015, Mr. Schnee served as a non-executive director of Cardiorentis Ltd., a biopharmaceutical company, where he served as Chairman and Chief Executive Officer from October 2011 until November 2013. From 2003 to 2011, Mr. Schnee held various positions at Merck KGaA, a global pharmaceutical and chemical group. He joined Merck KGaA in 2003 as Managing Director of Merck Santé S.A.S. In January 2004, Mr. Schnee assumed responsibility for global operations of the ethical pharmaceuticals division of Merck KGaA, and in November 2005, Mr. Schnee was appointed as Deputy Member of the Executive Board responsible for the pharmaceuticals business. In 2006, he was appointed as a member of the Executive Board and General Partner of Merck KGaA, with responsibility for global pharmaceutical activities, and served in this position until 2011. Prior to Merck KGaA, Mr. Schnee held senior positions in strategy, business development and marketing at UCB SA, Sanofi-Synthélabo SA, Migliara/Kaplan Associates, Inc. and Fisons Pharmaceuticals PLC. In addition, Mr. Schnee currently serves on the boards of directors of two pharmaceutical companies, Stallergenes-Greer and Santhera Pharmaceuticals Holding AG, and four privately-held life sciences companies. Mr. Schnee holds both a bachelor’s degree in marketing and a master’s degree in marketing and general management from the Swiss Institute of Business Administration in Zurich. With his experience as Chairman and Chief Executive Officer of Cardiorentis Ltd., his operational experience at Merck KGaA and other companies.

What is the salary of Elmar Schnee?

As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Elmar Schnee at Jazz Pharmaceuticals plc is 542,573$. There are 15 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of 14,713,600$.

How old is Elmar Schnee?

Elmar Schnee is 61, he's been the Independent Director of Jazz Pharmaceuticals plc since 2014. There are 5 older and 23 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.

What's Elmar Schnee's mailing address?

Elmar's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .

Insiders trading at Jazz Pharmaceuticals plc

Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over 1,513,676,247$ worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth 25,188,964$ . The most active insiders traders include Michael W Michelson、Patrick G Enright、Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of 5,162,934$. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth 152,703$.

What does Jazz Pharmaceuticals plc do?

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Complete history of Mr. Schnee stock trades at Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc executives and stock owners

Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Bruce Cozadd,
  Chairman of the Board, Chief Executive Officer
• Daniel Swisher,
  President, Chief Operating Officer
• Robert Iannone,
  Executive Vice President, Research and Development
• Neena Patil,
  Senior Vice President, General Counsel
• Bruce C. Cozadd,
  Co-Founder, Chairman & CEO
• Daniel N. Swisher Jr.,
  Pres
• Anne O'Riordan,
  Independent Director
• Dr. Robert Iannone M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Renee D. Gala,
  Exec. VP & CFO
• Kim Sablich,
  Exec. VP & GM of North America
• Rick Winningham,
  Independent Director
• Heather McSharry,
  Independent Director
• Peter Gray,
  Independent Director
• Norbert Riedel,
  Independent Director
• Patrick Enright,
  Independent Director
• Catherine Sohn,
  Independent Director
• Elmar Schnee,
  Independent Director
• Seamus Mulligan,
  Independent Director
• Kenneth O'Keefe,
  Independent Director
• Paul Berns,
  Independent Director
• Diane Schrick,
  Senior Director, Investor Relations
• Patricia Carr,
  Vice President, Finance and Principal Accounting Officer
• Samantha Pearce,
  Senior Vice President, Europe and Rest of World
• Finbar Larkin,
  Senior Vice President - Technical Operations
• Kimberly Sablich,
  Executive Vice President, General Manager - North America
• Renee Gala,
  Chief Financial Officer, Executive Vice President
• Neena M. Patil J.D.,
  Chief Legal Officer and Sr. VP of Legal & Corp. Affairs
• Andrea N. Flynn,
  VP & Head of Investor Relations
• Dr. Finbar Larkin Ph.D.,
  Sr. VP of Technical Operations
• Patricia Carr,
  VP of Fin. & Principal Accounting Officer
• Christopher John Tovey,
  Exec. VP, COO and MD of Europe & International
• Paul Treacy,
  SVP, Technical Operations
• Suzanne Sawochka Hooper,
  EVP and General Counsel
• Karen L. Smith,
  Global Head of R&D and CMO
• Karen J Wilson,
  VP of Finance & PAO
• Russell J. Cox,
  SVP, Sales and Marketing
• Iain Mc Gill,
  Head of EUSA Int'l & SVP
• Matthew P. Young,
  SVP & CFO
• Michael Patrick Miller,
  EVP, US Commercial
• Jennifer E. Cook,
  Director
• Mark Douglas Smith,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Bryan C Cressey,
  Director
• Alan Sebulsky,
  Director
• Kathryn E Falberg,
  SVP and CFO
• Paul Egolkin Perryhuth Joha...,
  
• Michael W Michelson,
  Director
• Samuel D Colella,
  Director
• Financial Holdings Iii, Llc...,
  
• Group Holdings L.P.Kkr Grou...,
  
• Matthew K Fust,
  Senior Vice President & CFO
• Jeffrey K Tobias,
  EVP, Research & Dev and CMO
• Fintan Keegan,
  EVP, Technical Operations
• Cressey Equity Partners Inc...,
  
• Mark G. Eller,
  SVP, Research & Clinical Dev.
• James C Momtazee,
  Director
• Jp Iii Llckkr Partners Iii,...,
  
• Fund Holdings L.P.Kkr Jp Ll...,
  
• Michael A. Des Jardin,
  SVP, Product Development
• Nathaniel M Zilkha,
  Director
• Joan Colligan,
  Principal Accounting Officer
• Janne Lt Wissel,
  Senior VP of Development
• James B Tananbaum,
  Director
• Samuel R Saks,
  Chief Executive Officer
• Robert M Myers,
  President
• E Alexander Albert,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Michael W Janetschek Willia...,
  
• Carol A Gamble,
  SVP, GC and Corporate Secty
• Management Llcmignone Rober...,
  
• Henry Rroberts George Rgree...,
  
• Michael Wkkr Financial Hold...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Patel Jaimin,
  Director
• Michael Wkkr Financial Hold...,
  
• Kim Sablich,
  EVP, GM of U.S.
• Mary Elizabeth Henderson,
  SVP, Technical Operations
• Christopher J. Tovey,
  EVP, COO & Managing Director E
• Laura Hamill,
  Director
• Patrick Kennedy,
  Director
• Philip L Johnson,
  EVP & Chief Financial Officer